Synergistic in vitro interactions between (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1.
Chemotherapy
; 52(1): 38-42, 2006.
Article
em En
| MEDLINE
| ID: mdl-16340198
The replication of herpes simplex virus (HSV) type 1 in Vero cells is inhibited in the presence of (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one (6b), a synthetic brassinosteroid derivative. Since a late step of virus multiplication is hindered by 6b, we performed studies of drug-drug combination with acyclovir (ACV) and foscarnet (FOS). It was determined that 6b would act synergistically with low concentrations of ACV and moderate concentrations of FOS against HSV. The best drug combination tested in this study resulted in an increase of 29.3 and 47.2% in antiviral activity for ACV (0.036 microM) and FOS (37.5 microM) in the presence of 14.8 and 6.9 microM of 6b, respectively.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Aciclovir
/
Colestanonas
/
Foscarnet
/
Herpesvirus Humano 1
Limite:
Animals
Idioma:
En
Revista:
Chemotherapy
Ano de publicação:
2006
Tipo de documento:
Article
País de afiliação:
Argentina
País de publicação:
Suíça